Key facts
| Recalling firm | Insulet Corporation |
|---|---|
| Manufacturer | Not disclosed in the FDA record. |
| Brand name | Not disclosed in the FDA record. |
| Product description | Omnipod (Eros) Pod. Includes the below Model/REF Numbers: 1. POD-ZXP425 (10 Pack), POD- ZXP420 (Single Pod). 2. ZXR425 (10-Pack), ZXR420 (Single Pod). 3. ZXP425 (10 Pack), ZXP420 (Single Pod). |
| Classification | Class I |
| Recall number | Z-2605-2026 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death. |
What this classification means
A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class I, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Omnipod (Eros) Pod. Includes the below Model/REF Numbers: 1. POD-ZXP425 (10 Pack), POD- ZXP420 (Single Pod). 2. ZXR425 (10-Pack), ZXR420 (Single Pod). 3. ZXP425 (10 Pack), ZXP420 (Single Pod). should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from Insulet Corporation. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from Insulet Corporation should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to Insulet Corporation directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
Insulet Corporation’s FDA history
Argus HQ has recorded 4 total FDA actions tied to Insulet Corporation: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- Is Omnipod (Eros) Pod. Includes the below Model/REF Numbers: recalled?
- Yes. FDA lists a Class I recall by Insulet Corporation for Omnipod (Eros) Pod. Includes the below Model/REF Numbers: 1. POD-ZXP425 (10 Pack), POD- ZXP420 (Single Pod). 2. ZXR425 (10-Pack), ZXR420 (Single Pod). 3. ZXP425 (10 Pack), ZXP420 (Single Pod)., reported 20260708, with status "Ongoing." FDA recall number: Z-2605-2026.
- What is the recall class for Insulet Corporation's recall?
- FDA classified this recall as Class I. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death.
- Why was Omnipod (Eros) Pod. Includes the below Model/REF Numbers: recalled?
- FDA's recall record states the reason as: External soft cannula damage during manufacturing that results in insulin leaking around the Pod instead of being delivered to the user regardless of basal or bolus delivery. The primary failure mode is pump under-delivery due to loss of insulin to an external leak. If insulin is not delivered properly, users may experience high blood glucose levels due to under-delivery of insulin. In the most severe cases, prolonged and persistent high blood glucose levels can lead to diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar syndrome (HHS), or even death.
- Who should I contact about this recall?
- Contact Insulet Corporation directly, or the distributor/pharmacy that supplied the product, to confirm whether your specific lot or unit is affected. Argus HQ aggregates the public FDA recall record and is not the recalling firm.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for Insulet CorporationCompiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Recall Database: Class I Recall: Omnipod (Eros) Pod. Includes the below Model/REF Numbers:… by Insulet Corporation. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/insulet-corporation-z-2605-2026-2026-07-08
"FDA Recall Database: Class I Recall: Omnipod (Eros) Pod. Includes the below Model/REF Numbers:… by Insulet Corporation." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/recall/insulet-corporation-z-2605-2026-2026-07-08.
Argus HQ Research. "FDA Recall Database: Class I Recall: Omnipod (Eros) Pod. Includes the below Model/REF Numbers:… by Insulet Corporation." Digital Empire Holdings LLC. Accessed August 27, 2026. https://argushq.ai/recall/insulet-corporation-z-2605-2026-2026-07-08.
@misc{argushq_argushq_ai_recall_insulet_corporation_z_2605_2026_2026_07_08_2026,
title = {FDA Recall Database: Class I Recall: Omnipod (Eros) Pod. Includes the below Model/REF Numbers:… by Insulet Corporation},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/insulet-corporation-z-2605-2026-2026-07-08},
note = {Accessed: August 27, 2026}
}Source: FDA.gov — Recalls ↗

